SEVERE/RESISTANT HYPERCHOLESTEROLEMIA: New Agents Redefining Clinical Practice
Registration

By clicking the continue button above, I certify that I have read the CME Statements below.

A Series of CME-certified Activities

FACULTY
‚Äč Eliot A. Brinton, MD, FAHA, FNLA
 Past President, American Board of Clinical Lipidology
 President, Utah Lipid Center
 Salty Lake City, UT

 

 

 

 Alan Brown, MD, FACC, FAHA, FNLA, FASPC
 President, National Lipid Association
 Director, Division of Cardiology
 Advocate Heart Institute at Advocate Lutheran General Hospital
 Co-Director, Advocate Medical Group
 Naperville, IL

 

 

PROGRAM OVERVIEW
Since hypercholesterolemia is a major driver of ASCVD, lipid-lowering therapies (mainly in combination with statins) are the primary approach to lower low-density lipoprotein cholesterol (LDL-C) and reduce CVD risk. Unfortunately, intensive statin therapy lowers CVD risk by only ~50%, leaving many patients at excessively high residual CVD risk. Recently approved PCSK9 inhibitors have been shown to produce robust LDL-C reduction (by ~60%) when co-administered with statins. Severe/Resistant Hypercholesterolemia: New Agents Redefining Clinical Practice will help clinicians develop a refined understanding of residual CVD risk in hypercholesterolemic patients and allow them to adjust prescribing behavior to reduce risk as much as possible.

AGENDA
Welcome, Introduction, and Pre-Survey
Guidelines, Trial Data, and Residual Risk
New and Emerging Treatment Options
Benefits and Limitations of Treatment Options
Q&A Session, Case Consult, and Concluding Remarks

TARGET AUDIENCE
This activity is intended for clinical cardiologists, internists, and other healthcare professionals who provide direct care to patients impacted by ASCVD.

EDUCATION OBJECTIVES
At the conclusion of this activity, participants should be able to:

  • Evaluate the relationship between residual hypercholesterolemia and residual CVD risk in high-risk patients
  • Define CVD risk elements to guide prescribing behavior
  • Differentiate the clinical properties of new and emerging pharmacologic approaches to reduce LDL-C and lower CVD risk
  • Analyze the potential strengths and weaknesses of new approaches to reduce CVD risk in combination with statins
  • Implement use of newer LDL-C lowering agents in combination with statins

PHYSICIAN ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT
Physicians: Boston University School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email cme@bu.edu.

Non-physicians: All other health care professionals will be issued a certificate of participation.

DISCLOSURE STATEMENT
This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

BOSTON UNIVERSITY SCHOOL OF MEDICINE DISCLAIMER
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

METHOD OF PARTICIPATION
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided upon submission of a completed evaluation form.

There are no fees associated with this program.

SPECIAL SERVICES
Event staff will be glad to assist you with any specials needs (e.g. physical, dietary, etc.).  Please email specialservices@rockpointe-pcme.com at least 5 days prior to the program.

 

Jointly provided by Boston University School of Medicine (BUSM) and Rockpointe

          

This activity is supported by educational funding donation provided by Amgen.